Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [¹⁸F]SiTATE.

ABSTRACT:

Objectives

Somatostatin receptor positron emission tomography/computed tomography (SSTR-PET/CT) using [⁶⁸Ga]-labeled tracers is a widely used imaging modality for neuroendocrine tumors (NET). Recently, [¹⁸F]SiTATE, a SiFAlin tagged [Tyr3]-octreotate (TATE) PET tracer, has shown great potential due to favorable clinical characteristics. We aimed to evaluate the reproducibility of Somatostatin Receptor-Reporting and Data System 1.0 (SSTR-RADS 1.0) for structured interpretation and treatment planning of NET using [¹⁸F]SiTATE.

Methods

Four readers assessed [¹⁸F]SiTATE-PET/CT of 95 patients according to the SSTR-RADS 1.0 criteria at two different time points. Each reader evaluated up to five target lesions per scan. The overall scan sco

SUBMITTER: Ebner R 

PROVIDER: S-EPMC11519286 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature